Sun-Novo(SH:688621) Zheng Quan Zhi Xing·2025-06-17 12:21Summary of Key Points Core Viewpoint The company, Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd., has announced changes to the use of raised funds, including the establishment of new special accounts for fundraising and the signing of tripartite supervision agreements to ensure proper management and allocation of these funds. Group 1: Fundraising Overview - The company was approved to publicly issue 20,000,000 shares at a price of 26.89 RMB per share, raising a total of 537.8 million RMB, with a net amount of 467.1815 million RMB after deducting issuance costs [1][2] - The funds are managed in special accounts with a tripartite supervision agreement signed with the sponsor and the supervising bank [2][4] Group 2: Changes in Fund Usage - The company has decided to change the use of surplus funds from completed projects to new projects, specifically the "Polypeptide Molecular Large Model Platform Project" and "Innovative Drug R&D Project" [3][4] - The special accounts for the new projects have been established at various banks, including Ningbo Bank and Industrial Bank, to ensure dedicated management of the funds [4][5] Group 3: Tripartite Supervision Agreement - The tripartite supervision agreements were signed with Minsheng Securities and the respective banks to regulate the management of the raised funds and protect investor interests [5][6] - The agreements stipulate that the funds must only be used for the designated projects and cannot be diverted for other purposes [5][6]